Sumitomo Pharma Co., Ltd. (DNPUF)
USD 4.13
(0.0%)
USD 4.13
(0.0%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 314.55 Billion | 555.54 Billion | 560.03 Billion | 515.95 Billion | 482.73 Billion | 459.26 Billion |
| Cost of Revenue | 126.57 Billion | 178.91 Billion | 157.12 Billion | 137.77 Billion | 129.67 Billion | 113.55 Billion |
| Gross Profit | 187.98 Billion | 376.62 Billion | 402.9 Billion | 378.17 Billion | 353.05 Billion | 345.71 Billion |
| Operating Expenses | 542.84 Billion | 453.6 Billion | 342.67 Billion | 306.95 Billion | 269.82 Billion | 287.83 Billion |
| Selling, General and Administrative Expenses | 429.53 Billion | 373.31 Billion | 249.08 Billion | 190.37 Billion | 154.34 Billion | 180.43 Billion |
| Research and Development Expenses | 112.63 Billion | 131.85 Billion | 94.9 Billion | 132.68 Billion | 115.11 Billion | 102.36 Billion |
| Other Expenses | 665 Million | - | - | - | - | - |
| Cost and Expenses | 669.41 Billion | 632.52 Billion | 499.8 Billion | 444.72 Billion | 399.49 Billion | 401.38 Billion |
| Operating Income | -354.85 Billion | -76.97 Billion | 60.23 Billion | 71.22 Billion | 83.23 Billion | 57.88 Billion |
| Interest Expense | 4.27 Billion | 3.15 Billion | 3.05 Billion | 2.58 Billion | 2.86 Billion | 207 Million |
| Income Tax Expense | -8.18 Billion | 48.79 Billion | 42.36 Billion | 41.02 Billion | 48.02 Billion | 16.41 Billion |
| Earnings before Tax | -323.11 Billion | -47.92 Billion | 82.96 Billion | 77.85 Billion | 83.94 Billion | 65.04 Billion |
| Net Income | -314.96 Billion | -74.51 Billion | 56.41 Billion | 56.21 Billion | 40.75 Billion | 48.62 Billion |
| Earnings Per Share Basic | -792.79 | -187.55 | 141.99 | 141.50 | 102.58 | 122.39 |
| Earnings Per Share Diluted | -792.79 | -187.55 | 141.99 | 141.50 | 102.58 | 122.39 |
| Weighted Average Shares Outstanding | 397.29 Million | 397.29 Million | 397.29 Million | 397.29 Million | 397.29 Million | 397.29 Million |
| Weighted Average Shares Outstanding (Diluted) | 397.29 Million | 397.29 Million | 397.29 Million | 397.29 Million | 397.29 Million | 397.29 Million |
| Gross Margin | 0.60 | 0.68 | 0.72 | 0.73 | 0.73 | 0.75 |
| EBIT Margin | -1.01 | -0.01 | 0.22 | 0.20 | 0.22 | 0.17 |
| Profit Margin | -1.00 | -0.13 | 0.10 | 0.11 | 0.08 | 0.11 |
| EBITDA | -317.37 Billion | -3.49 Billion | 98.31 Billion | 76.97 Billion | 100.28 Billion | 75.24 Billion |
| Earnings Before Tax Margin | -1.13 | -0.14 | 0.11 | 0.14 | 0.17 | 0.13 |
| Breakdown | 2024 FY | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY |
|---|---|---|---|---|---|---|
| Revenue | 314.55 Billion | 79.53 Billion | 82.38 Billion | 76.95 Billion | 75.68 Billion | 555.54 Billion |
| Cost of Revenue | 157.47 Billion | 33.38 Billion | 32.86 Billion | 29.89 Billion | 30.43 Billion | 178.91 Billion |
| Gross Profit | 157.07 Billion | 46.14 Billion | 49.51 Billion | 47.06 Billion | 45.25 Billion | 376.62 Billion |
| Operating Expenses | 158.55 Billion | 94.66 Billion | 80.76 Billion | 81.99 Billion | 96.82 Billion | 453.6 Billion |
| Selling, General and Administrative Expenses | - | 55.67 Billion | 57.51 Billion | 59.15 Billion | 74.89 Billion | - |
| Research and Development Expenses | - | 38.99 Billion | 23.29 Billion | 22.51 Billion | 27.84 Billion | - |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 316.03 Billion | 128.05 Billion | 113.63 Billion | 111.88 Billion | 127.25 Billion | 632.52 Billion |
| Operating Income | -1.47 Billion | -48.52 Billion | -31.24 Billion | -34.93 Billion | -51.56 Billion | -76.97 Billion |
| Interest Expense | 4.27 Billion | 1.54 Billion | 17.81 Billion | 851 Million | 800 Million | 3.15 Billion |
| Income Tax Expense | -8.18 Billion | -20.69 Billion | 899 Million | 3.79 Billion | 7.81 Billion | 48.79 Billion |
| Earnings before Tax | -323.11 Billion | -217.92 Billion | -49.06 Billion | -25.07 Billion | -31.05 Billion | -47.92 Billion |
| Net Income | -314.96 Billion | -197.26 Billion | -49.96 Billion | -28.87 Billion | -38.85 Billion | -74.51 Billion |
| Earnings Per Share Basic | - | -496.52 | -125.77 | -72.68 | -97.81 | - |
| Earnings Per Share Diluted | - | -496.52 | -125.77 | -72.68 | -97.81 | - |
| Weighted Average Shares Outstanding | 397.29 Million | 397.29 Million | 397.29 Million | 397.29 Million | 397.29 Million | 397.29 Million |
| Weighted Average Shares Outstanding (Diluted) | 397.29 Million | 397.29 Million | 397.29 Million | 397.29 Million | 397.29 Million | 397.29 Million |
| Gross Margin | 0.50 | 0.58 | 0.60 | 0.61 | 0.60 | 0.68 |
| EBIT Margin | - | -0.49 | -0.26 | -0.19 | -0.28 | - |
| Profit Margin | -1.00 | -2.48 | -0.61 | -0.38 | -0.51 | -0.13 |
| EBITDA | - | -39.02 Billion | -21.64 Billion | -14.78 Billion | -21.03 Billion | - |
| Earnings Before Tax Margin | -0.00 | -0.61 | -0.38 | -0.45 | -0.68 | -0.14 |
3918
EMA-PH
MHO
2016
UEPCO
AVTBF